In rodents and non-human primates, FGF21 treatment has beneficial effects on cardiometabolic outcomes, such as reduction in fat mass and alleviation of hyperglycaemia, insulin resistance, dyslipidaemia, and cardiovascular diseases (30). This evidence concerns the gene FGF21 and inherited lipid metabolism disorder.